Flerie AB

Net Asset Value • Oct 4, 2024

NET ASSET VALUE – 30 September 2024

On the 30 September 2024 Flerie AB's Net Asset Value (NAV) was SEK 4,262 million and NAV per share was SEK 54.59.

	Share of portfolio	Fair value	Part of NAV per share	Share of
Allocation of NAV	company	(MSEK)	(SEK)	NAV
Product Development
Prokarium	42%	475	6.09	11.1%
Xspray Pharma	18%	294	3.77	6.9%
Empros Pharma	79%	204	2.62	4.8%
KAHR Medical	31%	191	2.44	4.5%
Atrogi	37%	176	2.25	4.1%
Xintela	56%	165	2.11	3.9%
Lipum	57%	164	2.10	3.8%
Microbiotica	11%	135	1.73	3.2%
Geneos Therapeutics	12%	97	1.24	2.3%
Mendus	24%	96	1.23	2.3%
EpiEndo Pharmaceuticals	9%	56	0.72	1.3%
Toleranzia	58%	56	0.71	1.3%
Synerkine Pharma	43%	52	0.67	1.2%
AnaCardio	19%	52	0.66	1.2%
Egetis Therapeutics	2%	37	0.47	0.9%
Buzzard Pharmaceuticals	14%	29	0.37	0.7%
Sixera Pharma	23%	26	0.33	0.6%
Alder Therapeutics	21%	17	0.22	0.4%
Vitara Biomedical	5%	13	0.17	0.3%
Amarna Therapeutics	58%	11	0.15	0.3%
Strike Pharma	16%	9	0.11	0.2%
Total		2,354	30.16	55.2%
Commercial Growth
NorthX Biologics	92%	189	2.42	4.4%
Symcel	31%	169	2.16	4.0%
Chromafora	31%	73	0.93	1.7%
Provell Pharmaceuticals	72%	69	0.88	1.6%
A3P Biomedical	8%	42	0.54	1.0%
Nanologica	39%	39	0.50	0.9%
Frontier Biosolutions	2%	19	0.24	0.4%
Bohus Biotech	45%	17	0.21	0.4%
Total		616	7.89	14.5%
Limited Partnerships, total		92	1.18	2.2%

NAV	4,262	54.59	100.0%
Other assets and liabilities	910	11.66	21.4%
Assets related to Portfolio companies	289	3.70	6.8%

* indirect shares in Provell Pharmaceuticals

For more information:

Ted Fjällman, CEO Email: ir@flerie.com

Flerie in brief

Flerie is an active long-term life science investor, with a broad and diversified portfolio of innovative companies based on pioneering science. We invest in product development and commercial growth opportunities globally alongside other leading investors, focusing predominantly on private companies that are otherwise difficult to access. Flerie's active ownership model, broad network and resources support and accelerate the development of the portfolio projects, creating value for shareholders. Flerie AB's ordinary share is listed on Nasdaq Stockholm with the ticker FLERIE. For further information please visit www.flerie.com

Attachments

NET ASSET VALUE – 30 September 2024